New hope for advanced breast cancer patients as novel drug combo enters clinical testing
NCT ID NCT07235176
Summary
This study is testing a new drug called QLS1304 in combination with standard hormone therapy for people with advanced ER+/HER2- breast cancer that has stopped responding to previous hormone treatments. The trial aims to find the safest and most effective dose and see if the combination can shrink tumors. It will enroll about 300 adult patients to check for side effects and early signs that the treatment is working.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ER+/HER2- BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Cancer Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.